You are here

Home » Content

DONÖR SPESİFİK TRANSFÜZYONLARIN (DST) ERKEN ve GEÇ DÖNEM RENAL ALLOGREFT FONKSİYONU ÜZERİNE ETKİSİ

THE EFFECT OF DONOR-SPECIFIC TRANSFUSIONS (DST ) ON SHORT AND LONG-TERM RENAL ALLOGRAFT FUNCTION

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In order to evaluate the effect of donor-speclflc blood transfusions (DST) on short- and long-term re¬nal allograft function, a group consisted of 20 patients who underwent DST was compared to 35 patients who received HLA-identical living related donor graft and 25 patients who received one-haplotyplc donor graft. After transplantation, the time in which serum cre-atinine levels returned to the normal range in DST (4.1 ± 2.3 days) and HLA-identical groups (4.3±2.6 days) was significantly shorter than those in the one-haplotype group (6.2 ± 3.2 days) (p<0.05). While in one patient of tHe DST group (5.0 %) and three pati¬ents of the HLA-identical group (8.6 %) the serum creatinine level was not decreased below to 1.5 mgldl, this number was six (24.0 %) in the one-haplotype group. In the first and second groups acute rejection incidence (respectively 25 % and 20 %) was lower than in the one-haplotype group (44 %), but these dif¬ferences were not statistically significant. In the DST group three-year graft survival (85.7%) was similar to HLA-identical group (85.2 %), and better than the one-haplotype group (78.9 %).We conclude that re¬sults similar to HLA-identical transplantation may be obtained using the DST procedure in poorly matched donor and recipient combinations.
Bookmark/Search this post with
Abstract (Original Language): 
Donör spesifik transfüzyonların (DST) erken ve geç dönem renal allogreft fonksiyonu üzerine etkisini değerlendirmek için; DST uygulanan 20 hastalık grup (1. Grup); iki haplotlp geçişil 35 hastadan oluşan (2. Grup) ve tek haplotlp geçişil 225 hastadan oluşan (3. Grup) gruplarla karşılaştırıldı. Transplantasyon sonrası serum kreatlninin normal sınırlara inme süresi DST grubunda (4.1±2.3 gün) ve HLA Idantlkgrupta (4.3±2.6gün), tek haplotlp gruba göre (6.2 ± 3.2 gün) anlamlı olarak kısa bulundu (p<0.05). DST grubundan bir (% 5.0) ve HLA idantik gruptan üç (% 8.6) hastada serum kreatinln düzeyi 1.5 mgldl'nin altına inmezken, bu sayı tek haplotip grubunda altı (% 24.0) idi. istatistiksel olarak anlam¬lı olmamakla beraber 1. Grupta (% 25) ve 2. Grupta (% 20) akut rejekslyon sıklığı, 3. Gruptan (% 44) dü¬şüktü. DST grubunda üç yıllık greft sürvl oranı (% 85.7) HLA idantik gruba (% 85.2) eş değer, tek haplotlp grubundan (% 78.9) daha iyi bulundu. Sonuç olarak, alıcı ile verici arasında yeterli bir doku uyumu olmayan olgularda DST uygulaması ile HLA idantik transplantasyonlara eş değer sonuçların elde edilebileceği kanısına varıldı.
FULL TEXT (PDF): 
PDF icon pdf_tndt_71.pdf
  • 1
13-16
  • Turkish

REFERENCES

References: 

1. Opelz G, Sengar DPS, Mickey MR, Terasaki PI: Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973; 5: 253-259.
2. Fuller TC, Demonico FL, Cosimi AB, Huggins GE, King M, Russell PS. Impact of blood transfusion on renal transplantation. Ann Surg 1978; 187: 211-218.
3. Salvatierra O, Vincenti F, Amend W, et al. Deliberate donor-specific blood transfusions prior to living related renal transplantation: A new approach. Ann Surg 1980; 192: 543-552.
4. Opelz G, Terasaki PI. Dominant effect of transfusions on kidney graft survival. Transplantation 1980; 29: 153-158.
5. Anderson CB, Sicard GA, Etheredge EE. Pretreatment of renal allograft recipients with azathioprine and donor-specific blood products. Surgery 1982; 92: 315.
6. Sanfilippo F, Vaughn WK, Bollinger RR, Spees EK. The influence of pre-transplant transfusions, using different blood products, on patient sensitisation and renal allog-raft survival. Transplantation 1984; 37: 350-356.
7. Glass NR, Miller DT, Sollinger HW, Belzer FO. A four-
year experience with donor blood transfusion protocols for living-donor renal transplantation. Transplantation 1985; 39: 615-619.
8. Burlingham WJ, Grailer A, Sondel PM, Sollinger HW.
Improved renal allograft survival following donor-speci¬fic transfusions. Transplantation 1988; 45: 127-132.
9. Opelz G (for the Collaborative Transplant Study): Impro¬ved kidney graft survival in nontransfused recipients. Transplant Proc 1987; 19: 149-152.
10. Terasaki PI, Mickey MR, Cecka M, Iwaki Y, Ciccarelli
J. Clinical kidney transplants 1988. Immunol Lett 1989; 21: 33-38.
11. Singal DP, Fagnilli L, Joseph S. Blood transfusion indu¬ce antiidiotypic antibodies in renal transplant patients.
Transplant Proc 1983; 15: 1005-1008.
12. Chapman JR, Ting A, Fisher M, Carter NP, Morris PL
Failure of platelet transfusion to improve human renal al-lograft survival. Transplantation 1986; 41: 468-473.
13. Scornik JC, Ireland JE, Howard RJ, et al. Role of regular and leukocyte-free blood transfusions in the generation of broad sensitisation. Transplantation 1984; 38: 594¬598.
14. Scornik JC, Salomon DR, Howard RJ, Pfaff WW. Pre¬vention of transfusion-induced broad sensitisation in re¬nal transplant recipients. Transplantation 1989; 47: 617¬620.
15. Hillis AN, Sells RA, Bone JM, et al. A prospective clini¬cal trial of cyclosporine and donor-specific transfusion versus donor-specific transfusion alone in living related allograft recipients. Transplant Proc 1985; 17: 1242¬1243.
16. Raftery M J, Lang CJ, O'Shea JM et al. Controlled trial of
azathioprine and cyclosporin to prevent anti-HLA antibo¬dies due to third-party transfusion. Nephrol Dial Trans¬plant 1988; 3: 671-675.
17. Jones MC, Stewart KN, Propper DJ, Catto GRD, Power
DA. The effect of cyclosporin administered during a third-party blood transfusion protocol on humoral immu¬ne responses. Nephrol Dial Transplant 1991; 6: 125-130.

Thank you for copying data from http://www.arastirmax.com